SCHEMBL16745451

SCHEMBL16745451

NC1=C(C2=C(N)C(=O)c3ccccc3C2=O)C(=O)c2ccccc2C1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.60
NPC1 O15118 7/20 0.60
ALDH1A1 P00352 5/20 0.60
MAPT P10636 4/20 0.60
POLB P06746 4/20 0.60
NSD2 O96028 3/20 0.60
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
CDC25B P30305 2/20 0.55
SMN1; SMN2 Q16637 6/20 0.52
PTPRC P08575 4/20 0.52
MAOA P21397 3/20 0.52
APAF1 O14727 3/20 0.52
TDP2 O95551 3/20 0.52
LMNA P02545 3/20 0.52
S100A4 P26447 3/20 0.52
BLM P54132 3/20 0.52
MAPK1 P28482 2/20 0.52
PLA2G1B P04054 2/20 0.52
PLCG1 P19174 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16297081 0.86 MAPT (0.56) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL29563346 0.86 RAB9A (0.68) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL1510327 0.86 RAB9A (0.68) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL6297709 0.81 MAPT (0.56) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL14003716 0.80 CDC25B (0.73) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL15716847 0.77 MAPT (0.66) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL6861561 0.75 APAF1 (0.61) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL228422 0.75 CDC25B (0.56) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL14660371 0.75 ALDH1A1 (1.00) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL4800950 0.75 MEN1 (0.50) RAB9ANPC1ALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9481662-B2 Seriniquinones, melanoma-specific anticancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-01 US disclosed
US-9481662-B2 Seriniquinones, melanoma-specific anticancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-01 US disclosed
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-28 US disclosed
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS SDHA, KLK3, BRDT RAB9A 2471/4885NPC1 3954/4885ALDH1A1 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.